{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T03:19:35Z","timestamp":1793935175080,"version":"4.8.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014630","name":"Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014630","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jcyt.2026.102057","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T17:28:46Z","timestamp":1768930126000},"page":"102057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Systemic lupus erythematosus patients eligible for chimeric antigen receptor T-cell therapy according to the 2024 EBMT and International Society for Cell and Gene Therapy expert-based recommendations: a 1-year clinical practice study in France"],"prefix":"10.1016","volume":"28","author":[{"given":"Martin","family":"Nivet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5521-4742","authenticated-orcid":false,"given":"Ingrid","family":"Munia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4562-766X","authenticated-orcid":false,"given":"Benjamin","family":"Crichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2320-7269","authenticated-orcid":false,"given":"Tamim","family":"Alsuliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta Di","family":"Blasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Sabbah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwan","family":"Le Tallec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sondess Hadj","family":"Khelifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9400-6555","authenticated-orcid":false,"given":"Cl\u00e9ment","family":"Beuvon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catney","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Jachiet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5919-9956","authenticated-orcid":false,"given":"Louis","family":"Terriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-204X","authenticated-orcid":false,"given":"Gregory","family":"Pugnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0868-5804","authenticated-orcid":false,"given":"Alexandre","family":"Maria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9969-9947","authenticated-orcid":false,"given":"Robin","family":"Dhote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0235-7890","authenticated-orcid":false,"given":"Pedro Henrique","family":"Prata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5391-5875","authenticated-orcid":false,"given":"Zora","family":"Marjanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4368-2502","authenticated-orcid":false,"given":"Mickey","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4041-1352","authenticated-orcid":false,"given":"Dominique","family":"Farge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10188","key":"10.1016\/j.jcyt.2026.102057_bib0001","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/S0140-6736(19)30546-X","article-title":"Novel paradigms in systemic lupus erythematosus","volume":"393","author":"D\u00f6rner","year":"2019","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102057_bib0002","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41590-020-0677-6","article-title":"Autoimmunity and organ damage in systemic lupus erythematosus","volume":"21","author":"Tsokos","year":"2020","journal-title":"Nat Immunol"},{"issue":"10441","key":"10.1016\/j.jcyt.2026.102057_bib0003","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/S0140-6736(24)00398-2","article-title":"Systemic lupus erythematosus","volume":"403","author":"Hoi","year":"2024","journal-title":"Lancet Lond Engl"},{"issue":"11","key":"10.1016\/j.jcyt.2026.102057_bib0004","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1093\/rheumatology\/kex260","article-title":"The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies","volume":"56","author":"Rees","year":"2017","journal-title":"Rheumatology"},{"issue":"Suppl 1","key":"10.1016\/j.jcyt.2026.102057_bib0005","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/rheumatology\/keac610","article-title":"The global epidemiology of SLE: narrowing the knowledge gaps","volume":"62","author":"Barber","year":"2023","journal-title":"Rheumatol Oxf Engl"},{"issue":"9","key":"10.1016\/j.jcyt.2026.102057_bib0006","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102057_bib0007","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"65","author":"Weening","year":"2004","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102057_bib0008","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrrheum.2015.159","article-title":"What is damaging the kidney in lupus nephritis?","volume":"12","author":"Davidson","year":"2016","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102057_bib0009","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/rheumatology\/kez516","article-title":"Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort","volume":"59","author":"Segura","year":"2020","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102057_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2020-000389","article-title":"Prediction of prognosis and renal outcome in lupus nephritis","volume":"7","author":"Parodis","year":"2020","journal-title":"Lupus Sci Med"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102057_bib0011","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/art.40729","article-title":"All-Cause and Cause-Specific Mortality Trends of End-Stage Renal Disease Due to Lupus Nephritis From 1995 to 2014","volume":"71","author":"Jorge","year":"2019","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.jcyt.2026.102057_bib0012","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejim.2023.02.004","article-title":"Mortality and causes of death in systemic lupus erythematosus over the last decade: Data from a large population-based study","volume":"112","author":"Zen","year":"2023","journal-title":"Eur J Intern Med"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102057_bib0013","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.jcyt.2026.102057_bib0014","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102057_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"issue":"17","key":"10.1016\/j.jcyt.2026.102057_bib0016","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic Lupus Erythematosus: A Review","volume":"331","author":"Siegel","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jcyt.2026.102057_bib0017","doi-asserted-by":"crossref","unstructured":"Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 26 377(9767):721\u201131.","DOI":"10.1016\/S0140-6736(10)61354-2"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102057_bib0018","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3899\/jrheum.100130","article-title":"Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis","volume":"38","author":"Touma","year":"2011","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.jcyt.2026.102057_bib0019","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102057_bib0020","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of Anifrolumab in Active Systemic Lupus Erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jcyt.2026.102057_bib0021","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/acr.25007","article-title":"Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis","volume":"75","author":"Arriens","year":"2023","journal-title":"Arthritis Care Res"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102057_bib0022","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41584-023-00925-5","article-title":"Treatment of lupus nephritis: consensus, evidence and perspectives","volume":"19","author":"Mok","year":"2023","journal-title":"Nat Rev Rheumatol"},{"issue":"1S","key":"10.1016\/j.jcyt.2026.102057_bib0023","first-page":"S1","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 Clinical Practice Guideline for the management of lupus nephritis","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102057_bib0024","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40265-022-01824-x","article-title":"Refractory Systemic Lupus Erythematosus: Identification and Pharmacological Management","volume":"83","author":"Roccatello","year":"2023","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102057_bib0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2008.102533","article-title":"The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102057_bib0026","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/0003-4819-135-4-200108210-00009","article-title":"Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis","volume":"135","author":"Illei","year":"2001","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.jcyt.2026.102057_bib0027","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1002\/art.22810","article-title":"Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy","volume":"56","author":"Anolik","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102057_bib0028","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jcyt.2026.102057_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103687","article-title":"Harnessing the potential of CAR-T cell in lupus treatment: From theory to practice","volume":"23","author":"Alsuliman","year":"2024","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jcyt.2026.102057_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102476","article-title":"Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee","volume":"69","author":"Greco","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.jcyt.2026.102057_bib0031","unstructured":"EBMT. 8th edition of FACT-JACIE standards. https:\/\/www.ebmt.org\/8th-edition-fact-jacie-standards; 2021 [accessed 17.09.25]."},{"issue":"2","key":"10.1016\/j.jcyt.2026.102057_bib0032","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.revmed.2023.12.008","article-title":"French protocol for the diagnosis and management of hematopoietic stem cell transplantation in autoimmune diseases","volume":"45","author":"Farge","year":"2024","journal-title":"Rev Med Interne"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102057_bib0033","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1016\/S2665-9913(24)00298-4","article-title":"Allogeneic umbilical cord-derived mesenchymal stromal cells as treatment for systemic lupus erythematosus: a single-centre, open-label, dose-escalation, phase 1 study","volume":"7","author":"Farge","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102057_bib0034","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00005792-199303000-00005","article-title":"Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus","volume":"72","author":"Cervera","year":"1993","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"10.1016\/j.jcyt.2026.102057_bib0035","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.amjmed.2005.11.034","article-title":"Long-term prognosis and causes of death in systemic lupus erythematosus","volume":"119","author":"Doria","year":"2006","journal-title":"Am J Med"},{"issue":"8","key":"10.1016\/j.jcyt.2026.102057_bib0036","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1136\/annrheumdis-2016-210382","article-title":"Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus","volume":"76","author":"Mok","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.jcyt.2026.102057_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102400","article-title":"ANA as an entry criterion for the classification of SLE","volume":"18","author":"Pisetsky","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.jcyt.2026.102057_bib0038","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.21955","article-title":"Mortality in systemic lupus erythematosus","volume":"54","author":"Bernatsky","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102057_bib0039","first-page":"167","article-title":"Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients","volume":"78","author":"Cervera","year":"1999","journal-title":"European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.jcyt.2026.102057_bib0040","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/01.md.0000091181.93122.55","article-title":"Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients","volume":"82","author":"Cervera","year":"2003","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"10.1016\/j.jcyt.2026.102057_bib0041","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1177\/0961203309106831","article-title":"The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe","volume":"18","author":"Cervera","year":"2009","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102057_bib0042","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.jcyt.2026.102057_bib0043","first-page":"447","article-title":"The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus","volume":"86","author":"Hay","year":"1993","journal-title":"Q J Med"},{"issue":"10","key":"10.1016\/j.jcyt.2026.102057_bib0044","doi-asserted-by":"crossref","first-page":"e786","DOI":"10.1016\/S2352-3026(22)00226-5","article-title":"Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper","volume":"9","author":"Gagelmann","year":"2022","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.jcyt.2026.102057_bib0045","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jtct.2025.05.012","article-title":"Setting up a Chimeric Antigen Receptor T Cell Therapy Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation","volume":"31","author":"Ahmed","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102057_bib0046","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/art.42784","article-title":"CD19 Chimeric Antigen Receptor T Cell Treatment: Unraveling the Role of B Cells in Systemic Lupus Erythematosus","volume":"76","author":"Taubmann","year":"2024","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"10","key":"10.1016\/j.jcyt.2026.102057_bib0047","doi-asserted-by":"crossref","first-page":"6346","DOI":"10.4049\/jimmunol.0901773","article-title":"Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8+ Treg cells are associated with immunological remission of lupus","volume":"183","author":"Zhang","year":"2009","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102057_bib0048","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.jcyt.2026.102057_bib0049","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.179433","article-title":"Selective CAR T cell-mediated B cell depletion suppresses IFN signature in SLE","volume":"9","author":"Wilhelm","year":"2024","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102057_bib0050","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ard.2025.06.2132","article-title":"Differential molecular signatures in response to CD19-CAR T cell therapy compared with conventional pharmacotherapy in systemic lupus erythematosus","volume":"85","author":"Garantziotis","year":"2026","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102057_bib0051","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.18209","article-title":"A national service for delivering CD19 CAR-Tin large B-cell lymphoma\u2014The UK real-world experience","volume":"198","author":"Kuhnl","year":"2022","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.jcyt.2026.102057_bib0052","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jcyt.2024.02.007","article-title":"Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT)","volume":"26","author":"Sanchez-Guijo","year":"2024","journal-title":"Cytotherapy"},{"issue":"10","key":"10.1016\/j.jcyt.2026.102057_bib0053","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102057_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103229","article-title":"Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Shu","year":"2025","journal-title":"eClinicalMedicine"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102057_bib0055","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2009.013458","article-title":"Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years\u2019 experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases","volume":"95","author":"Farge","year":"2010","journal-title":"Haematologica"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926000137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926000137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T07:17:31Z","timestamp":1782199051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926000137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1465324926000137"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102057","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic lupus erythematosus patients eligible for chimeric antigen receptor T-cell therapy according to the 2024 EBMT and International Society for Cell and Gene Therapy expert-based recommendations: a 1-year clinical practice study in France","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102057"}}